

Sub. H. B. No. 193  
As Passed by the House

\_\_\_\_\_ moved to amend as follows:

In line 1 of the title, after "sections" insert "2925.61, 3707.56, 1  
3707.561, 3707.562,"; delete "and" and insert ","; after "3719.06" insert 2  
", 4723.484, 4723.485, 4723.486, 4729.01, 4729.29, 4729.44, 4729.51, 3  
4729.511, 4729.514, 4729.515, 4729.541, 4730.434, 4730.435, 4730.436, 4  
4731.94, 4731.941, 4731.942, 4731.943, 4765.44, 4765.45, and 4765.52" 5

In line 3 of the title, after "substances" insert "and terminology 6  
related to overdose reversal drugs" 7

In line 4, after "sections" insert "2925.61, 3707.56, 3707.561, 8  
3707.562,"; delete "and" and insert ","; after "3719.06" insert ", 9  
4723.484, 4723.485, 4723.486, 4729.01, 4729.29, 4729.44, 4729.51, 10  
4729.511, 4729.514, 4729.515, 4729.541, 4730.434, 4730.435, 4730.436, 11  
4731.94, 4731.941, 4731.942, 4731.943, 4765.44, 4765.45, and 4765.52" 12

After line 5, insert: 13

**"Sec. 2925.61.** (A) As used in this section: 14

(1) "Law enforcement agency" means a government entity 15  
that employs peace officers to perform law enforcement duties. 16



(2) "Licensed health professional" means all of the following: 17  
18

(a) A physician; 19

(b) A physician assistant who is licensed under Chapter 4730. of the Revised Code, holds a valid prescriber number issued by the state medical board, and has been granted physician-delegated prescriptive authority; 20  
21  
22  
23

(c) An advanced practice registered nurse who holds a current, valid license issued under Chapter 4723. of the Revised Code and is designated as a clinical nurse specialist, certified nurse-midwife, or certified nurse practitioner. 24  
25  
26  
27

(3) "Overdose reversal drug" has the same meaning as in section 4729.01 of the Revised Code. 28  
29

(4) "Peace officer" has the same meaning as in section 2921.51 of the Revised Code. 30  
31

~~(4)~~ (5) "Physician" means an individual who is authorized under Chapter 4731. of the Revised Code to practice medicine and surgery, osteopathic medicine and surgery, or podiatric medicine and surgery. 32  
33  
34  
35

(B) A family member, friend, or other individual who is in a position to assist an individual who is apparently experiencing or at risk of experiencing an opioid-related overdose is not subject to criminal prosecution for a violation of section 4731.41 of the Revised Code, is not subject to criminal prosecution under this chapter, and is not liable for damages in a civil action for injury, death, or loss to person or property for an act or omission that allegedly arises from obtaining, maintaining, accessing, or administering 36  
37  
38  
39  
40  
41  
42  
43  
44

~~naloxone~~overdose reversal drugs, if the individual, acting in good faith, does all of the following:

(1) Obtains ~~naloxone~~overdose reversal drugs pursuant to a prescription issued by a licensed health professional, or obtains ~~naloxone~~overdose reversal drugs from one of the following:

(a) A licensed health professional;

(b) An individual who is authorized to personally furnish ~~naloxone~~overdose reversal drugs by any of the following:

(i) A physician under section 4731.941 of the Revised Code;

(ii) An advanced practice registered nurse under section 4723.485 of the Revised Code;

(iii) A physician assistant under section 4730.435 of the Revised Code;

(iv) A board of health under section 3707.561 of the Revised Code.

(c) A pharmacist or pharmacy intern who is authorized by a physician or board of health under section 4729.44 of the Revised Code to dispense ~~naloxone~~overdose reversal drugs without a prescription.

(2) Administers ~~the naloxone~~an overdose reversal drug obtained as described in division (B)(1) of this section to an individual who is apparently experiencing an opioid-related overdose;

(3) Attempts to summon emergency services as soon as practicable either before or after administering the

~~naloxone~~overdose reversal drug. 72

(C) An individual who is an employee, volunteer, or 73  
contractor of a service entity, as defined in section 4729.514 74  
of the Revised Code, and has been authorized under section 75  
3707.562, 4723.486, 4730.436, or 4731.943 of the Revised Code to 76  
administer ~~naloxone~~overdose reversal drugs is not subject to 77  
criminal prosecution for a violation of section 4731.41 of the 78  
Revised Code or criminal prosecution under this chapter, if the 79  
individual, acting in good faith, does all of the following: 80

(1) Obtains ~~naloxone~~overdose reversal drugs from the 81  
service entity of which the individual is an employee, 82  
volunteer, or contractor; 83

(2) Administers ~~the naloxone~~an overdose reversal drug 84  
obtained to an individual who is apparently experiencing an 85  
opioid-related overdose; 86

(3) Attempts to summon emergency services as soon as 87  
practicable either before or after administering the ~~naloxone~~ 88  
overdose reversal drug. 89

(D) Divisions (B) and (C) of this section do not apply to 90  
a peace officer or to an emergency medical technician-basic, 91  
emergency medical technician-intermediate, or emergency medical 92  
technician-paramedic, as defined in section 4765.01 of the 93  
Revised Code. 94

(E) (1) If a peace officer, acting in good faith, 95  
administers ~~naloxone~~an overdose reversal drug to an individual 96  
who is apparently experiencing an opioid-related overdose, both 97  
of the following apply: 98

(a) The peace officer is not subject to administrative 99

action, criminal prosecution for a violation of section 4731.41 100  
of the Revised Code, or criminal prosecution under this chapter. 101

(b) The peace officer is not liable for damages in a civil 102  
action for injury, death, or loss to person or property for an 103  
act or omission that allegedly arises from obtaining, 104  
maintaining, accessing, or administering the ~~naloxone~~ overdose 105  
reversal drug. 106

(2) Division (E)(1)(b) of this section does not eliminate, 107  
limit, or reduce any other immunity or defense that an entity or 108  
person may be entitled to under section 9.86 or Chapter 2744. of 109  
the Revised Code, any other provision of the Revised Code, or 110  
the common law of this state. 111

**Sec. 3707.56.** (A) As used in this section and in sections 112  
3707.561 and 3707.562 of the Revised Code, ~~"board":~~ 113

(1) "Board of health" means a board of health of a city or 114  
general health district or the authority having the duties of a 115  
board of health under section 3709.05 of the Revised Code. 116

(2) "Overdose reversal drug" has the same meaning as in 117  
section 4729.01 of the Revised Code. 118

(B) A board of health, through a physician serving as the 119  
board's health commissioner or medical director, may authorize 120  
pharmacists and pharmacy interns practicing pharmacy in a county 121  
that includes all or part of the health district represented by 122  
the board to use the protocol developed pursuant to rules 123  
adopted under section 4729.44 of the Revised Code for the 124  
purpose of dispensing ~~naloxone~~ overdose reversal drugs under 125  
section 4729.44 of the Revised Code. 126

**Sec. 3707.561.** (A) A board of health that establishes a 127

protocol under division (C) of this section may, through a 128  
physician serving as the board's health commissioner or medical 129  
director, authorize one or more individuals to personally 130  
furnish a supply of ~~naloxone~~ overdose reversal drugs pursuant to 131  
the protocol to either of the following: 132

(1) An individual who there is reason to believe is 133  
experiencing or at risk of experiencing an opioid-related 134  
overdose; 135

(2) A family member, friend, or other person in a position 136  
to assist an individual who there is reason to believe is at 137  
risk of experiencing an opioid-related overdose. 138

(B) (1) An individual authorized under this section may 139  
personally furnish ~~naloxone~~ overdose reversal drugs to an 140  
individual described in division (A) of this section if both of 141  
the following conditions are met: 142

(a) The authorized individual complies with the protocol 143  
established by the authorizing board, including having completed 144  
the training required by the protocol. 145

(b) The authorized individual instructs the individual to 146  
whom ~~naloxone is~~ overdose reversal drugs are furnished to summon 147  
emergency services as soon as practicable either before or after 148  
administering ~~naloxone~~ such drugs. 149

(2) An individual authorized under this section to 150  
personally furnish ~~naloxone~~ overdose reversal drugs may do so 151  
without having examined the individual to whom it may be 152  
administered. 153

(C) A board of health, through a physician serving as the 154  
board's health commissioner or medical director, may establish a 155

protocol for personally furnishing <del>naloxone</del> <u>overdose reversal</u>	156
<u>drugs</u> under division (A) of this section. The protocol must be	157
in writing and include all of the following:	158
(1) A description of the clinical pharmacology of <del>naloxone</del>	159
<u>the overdose reversal drugs specified in the protocol;</u>	160
(2) Precautions and contraindications concerning	161
furnishing <del>naloxone</del> <u>overdose reversal drugs;</u>	162
(3) Any limitations the board specifies concerning the	163
individuals to whom <del>naloxone</del> <u>overdose reversal drugs</u> may be	164
furnished;	165
(4) The <del>naloxone</del> dosage that may be furnished and any	166
variation in the dosage based on circumstances specified in the	167
protocol;	168
(5) Labeling, storage, record keeping, and administrative	169
requirements;	170
(6) Training requirements that must be met before an	171
individual can be authorized to furnish <del>naloxone</del> <u>overdose</u>	172
<u>reversal drugs;</u>	173
(7) Any instructions or training the authorized individual	174
must provide to an individual to whom <del>naloxone is</del> <u>overdose</u>	175
<u>reversal drugs are</u> furnished.	176
(D) A board that in good faith authorizes an individual to	177
personally furnish <del>naloxone</del> <u>overdose reversal drugs</u> under this	178
section is not liable for damages in any civil action for any	179
act or omission of the individual to whom the <del>naloxone is</del> <u>drugs</u>	180
<u>are</u> furnished.	181
A physician serving as a board's health commissioner or	182
medical director who in good faith authorizes an individual to	183

personally furnish ~~naloxone~~ overdose reversal drugs under this 184  
section is not liable for or subject to any of the following for 185  
any act or omission of the individual to whom the ~~naloxone is~~ 186  
drugs are furnished: damages in any civil action, prosecution in 187  
any criminal proceeding, or professional disciplinary action. 188

An individual authorized under this section to personally 189  
furnish ~~naloxone~~ overdose reversal drugs who does so in good 190  
faith is not liable for or subject to any of the following for 191  
any act or omission of the individual to whom the ~~naloxone is~~ 192  
drugs are furnished: damages in any civil action, prosecution in 193  
any criminal proceeding, or professional disciplinary action. 194

**Sec. 3707.562.** (A) As used in this section, "service 195  
entity" has the same meaning as in section 4729.514 of the 196  
Revised Code. 197

(B) A board of health that has established a protocol 198  
under division (D) of this section may authorize an individual 199  
who is an employee, volunteer, or contractor of a service entity 200  
to administer ~~naloxone~~ overdose reversal drugs to an individual 201  
who is apparently experiencing an opioid-related overdose. 202

(C) An individual authorized by a board of health under 203  
this section may administer ~~naloxone~~ overdose reversal drugs to 204  
an individual who is apparently experiencing an opioid-related 205  
overdose if both of the following conditions are met: 206

(1) The authorized individual complies with the protocol 207  
established by the board. 208

(2) The authorized individual summons emergency services 209  
as soon as practicable either before or after administering ~~the~~ 210  
~~naloxone~~ an overdose reversal drug. 211



(D) A board of health, through a physician serving as the board's health commissioner or medical director, may establish a protocol for administering ~~naloxone~~ overdose reversal drugs under this section. The protocol must be established in writing and include all of the following:

(1) A description of the clinical pharmacology of ~~naloxone~~ the overdose reversal drugs specified in the protocol;

(2) Precautions and contraindications concerning the administration of ~~naloxone~~ overdose reversal drugs;

(3) Any limitations the board specifies concerning the individuals to whom ~~naloxone~~ overdose reversal drugs may be administered;

(4) The ~~naloxone~~ dosage that may be administered and any variation in the dosage based on circumstances specified in the protocol;

(5) Labeling, storage, record keeping, and administrative requirements;

(6) Training requirements that must be met before an individual can be authorized to administer ~~naloxone~~ overdose reversal drugs.

(E) A board that in good faith authorizes an individual to administer ~~naloxone~~ overdose reversal drugs under this section is not liable for damages in any civil action for any act or omission of the authorized individual.

A physician serving as a board's health commissioner or medical director who in good faith authorizes an individual to administer ~~naloxone~~ overdose reversal drugs under this section is not liable for or subject to any of the following for any act

or omission of the authorized individual: damages in any civil 240  
action, prosecution in any criminal proceeding, or professional 241  
disciplinary action. 242

A service entity or an employee, volunteer, or contractor 243  
of a service entity is not liable for or subject to any of the 244  
following for injury, death, or loss to person or property that 245  
allegedly arises from an act or omission associated with 246  
procuring, maintaining, accessing, or using ~~naloxone~~ overdose 247  
reversal drugs under this section, unless the act or omission 248  
constitutes willful or wanton misconduct: damages in any civil 249  
action, prosecution in any criminal proceeding, or professional 250  
disciplinary action. 251

This section does not eliminate, limit, or reduce any 252  
other immunity or defense that a service entity or an employee, 253  
volunteer, or contractor of a service entity may be entitled to 254  
under Chapter 2305. or any other provision of the Revised Code 255  
or under the common law of this state." 256

After line 134, insert: 257

**"Sec. 4723.484.** (A) As used in this section and in 258  
sections 4723.485 and 4723.486 of the Revised Code, "overdose 259  
reversal drug" has the same meaning as in section 4729.01 of the 260  
Revised Code. 261

(B) Notwithstanding any provision of this chapter or rule 262  
adopted by the board of nursing, an advanced practice registered 263  
nurse who is designated as a clinical nurse specialist, 264  
certified nurse-midwife, or certified nurse practitioner may 265  
personally furnish a supply of ~~naloxone~~ overdose reversal drugs, 266  
or issue a prescription for ~~naloxone~~ overdose reversal drugs, 267  
without having examined the individual to whom it may be 268

administered if both of the following conditions are met: 269

(1) The ~~naloxone~~ supply is furnished to, or the 270  
prescription is issued to and in the name of, a family member, 271  
friend, or other individual in a position to assist an 272  
individual who there is reason to believe is at risk of 273  
experiencing an opioid-related overdose. 274

(2) The advanced practice registered nurse instructs the 275  
individual receiving the ~~naloxone~~ supply or prescription to 276  
summon emergency services as soon as practicable either before 277  
or after administering ~~naloxone~~ an overdose reversal drug to an 278  
individual apparently experiencing an opioid-related overdose. 279

~~(B)~~ (C) An advanced practice registered nurse who under 280  
division ~~(A)~~ (B) of this section in good faith furnishes a 281  
supply of ~~naloxone~~ overdose reversal drugs or issues a 282  
prescription for ~~naloxone~~ overdose reversal drugs is not liable 283  
for or subject to any of the following for any action or 284  
omission of the individual to whom the ~~naloxone~~ is overdose 285  
reversal drugs are furnished or the prescription is issued: 286  
damages in any civil action, prosecution in any criminal 287  
proceeding, or professional disciplinary action. 288

**Sec. 4723.485.** (A) (1) An advanced practice registered 289  
nurse who is designated as a clinical nurse specialist, 290  
certified nurse-midwife, or certified nurse practitioner and who 291  
has established a protocol that meets the requirements of 292  
division (C) of this section may authorize one or more other 293  
individuals to personally furnish a supply of ~~naloxone~~ overdose 294  
reversal drugs pursuant to the protocol to either of the 295  
following: 296

(a) An individual who there is reason to believe is 297

experiencing or at risk of experiencing an opioid-related overdose; 298  
299

(b) A family member, friend, or other person in a position to assist an individual who there is reason to believe is at risk of experiencing an opioid-related overdose. 300  
301  
302

(2) An individual authorized under this section to personally furnish ~~naloxone~~ overdose reversal drugs may do so without having examined the individual to whom it may be administered. 303  
304  
305  
306

(B) An individual authorized by an advanced practice registered nurse under this section may personally furnish ~~naloxone~~ overdose reversal drugs to an individual described in division (A) (1) (a) or (b) of this section if both of the following conditions are met: 307  
308  
309  
310  
311

(1) The authorized individual complies with the protocol established by the authorizing advanced practice registered nurse, including having completed the training required by the protocol. 312  
313  
314  
315

(2) The authorized individual instructs the individual to whom ~~naloxone is~~ overdose reversal drugs are furnished to summon emergency services as soon as practicable either before or after administering ~~naloxone~~ the drug. 316  
317  
318  
319

(C) A protocol established by an advanced practice registered nurse for purposes of this section shall be established in writing and include all of the following: 320  
321  
322

(1) A description of the clinical pharmacology of ~~naloxone~~ the overdose reversal drugs specified in the protocol; 323  
324

(2) Precautions and contraindications concerning 325

furnishing ~~naloxone~~ overdose reversal drugs; 326

(3) Any limitations the advanced practice registered nurse 327  
specifies concerning the individuals to whom ~~naloxone~~ overdose 328  
reversal drugs may be furnished; 329

(4) The ~~naloxone~~ dosage that may be furnished and any 330  
variation in the dosage based on circumstances specified in the 331  
protocol; 332

(5) Labeling, storage, record keeping, and administrative 333  
requirements; 334

(6) Training requirements that must be met before an 335  
individual will be authorized to furnish ~~naloxone~~ overdose 336  
reversal drugs; 337

(7) Any instructions or training that the authorized 338  
individual must provide to an individual to whom ~~naloxone is~~ 339  
overdose reversal drugs are furnished. 340

(D) An advanced practice registered nurse who in good 341  
faith authorizes another individual to personally furnish 342  
~~naloxone~~ overdose reversal drugs in accordance with a protocol 343  
established by the advanced practice registered nurse under this 344  
section is not liable for or subject to any of the following for 345  
any action or omission of the individual to whom the ~~naloxone is~~ 346  
drugs are furnished: damages in any civil action, prosecution in 347  
any criminal proceeding, or professional disciplinary action. 348

An individual authorized under this section to personally 349  
furnish ~~naloxone~~ overdose reversal drugs who does so in good 350  
faith is not liable for or subject to any of the following for 351  
any action or omission of the individual to whom the ~~naloxone is~~ 352  
drugs are furnished: damages in any civil action, prosecution in 353

any criminal proceeding, or professional disciplinary action. 354

**Sec. 4723.486.** (A) As used in this section, "service 355  
entity" has the same meaning as in section 4729.514 of the 356  
Revised Code. 357

(B) An advanced practice registered nurse who is 358  
designated as a clinical nurse specialist, certified nurse- 359  
midwife, or certified nurse practitioner and who has established 360  
a protocol under division (D) of this section may authorize an 361  
individual who is an employee, volunteer, or contractor of a 362  
service entity to administer ~~naloxone~~ overdose reversal drugs to 363  
an individual who is apparently experiencing an opioid-related 364  
overdose. 365

(C) An individual authorized by an advanced practice 366  
registered nurse under this section may administer ~~naloxone~~ 367  
overdose reversal drugs to an individual who is apparently 368  
experiencing an opioid-related overdose if all of the following 369  
conditions are met: 370

(1) The ~~naloxone is~~ overdose reversal drugs are obtained 371  
from a service entity of which the authorized individual is an 372  
employee, volunteer, or contractor. 373

(2) The authorized individual complies with the protocol 374  
established by the authorizing advanced practice registered 375  
nurse. 376

(3) The authorized individual summons emergency services 377  
as soon as practicable either before or after administering the- 378  
~~naloxone~~ overdose reversal drugs. 379

(D) A protocol established by an advanced practice 380  
registered nurse for purposes of this section must be in writing 381

and include all of the following:	382
(1) A description of the clinical pharmacology of <del>naloxone</del> <u>the overdose reversal drugs specified in the protocol;</u>	383 384
(2) Precautions and contraindications concerning the administration of <del>naloxone</del> <u>overdose reversal drugs;</u>	385 386
(3) Any limitations the advanced practice registered nurse specifies concerning the individuals to whom <del>naloxone</del> <u>overdose</u> <u>reversal drugs</u> may be administered;	387 388 389
(4) The <del>naloxone</del> dosage that may be administered and any variation in the dosage based on circumstances specified in the protocol;	390 391 392
(5) Labeling, storage, record keeping, and administrative requirements;	393 394
(6) Training requirements that must be met before an individual can be authorized to administer <del>naloxone</del> <u>overdose</u> <u>reversal drugs.</u>	395 396 397
(E) An advanced practice registered nurse who in good faith authorizes an individual to administer <del>naloxone</del> <u>overdose</u> <u>reversal drugs</u> under this section is not liable for or subject to any of the following for any act or omission of the authorized individual: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	398 399 400 401 402 403
A service entity or an employee, volunteer, or contractor of a service entity is not liable for or subject to any of the following for injury, death, or loss to person or property that allegedly arises from an act or omission associated with procuring, maintaining, accessing, or administering <del>naloxone</del> <u>overdose reversal drugs</u> under this section, unless the act or	404 405 406 407 408 409

omission constitutes willful or wanton misconduct: damages in 410  
any civil action, prosecution in any criminal proceeding, or 411  
professional disciplinary action. 412

This section does not eliminate, limit, or reduce any 413  
other immunity or defense that a service entity or an employee, 414  
volunteer, or contractor of a service entity may be entitled to 415  
under Chapter 2305. or any other provision of the Revised Code 416  
or under the common law of this state. 417

**Sec. 4729.01.** As used in this chapter: 418

(A) "Pharmacy," except when used in a context that refers 419  
to the practice of pharmacy, means any area, room, rooms, place 420  
of business, department, or portion of any of the foregoing 421  
where the practice of pharmacy is conducted. 422

(B) "Practice of pharmacy" means providing pharmacist care 423  
requiring specialized knowledge, judgment, and skill derived 424  
from the principles of biological, chemical, behavioral, social, 425  
pharmaceutical, and clinical sciences. As used in this division, 426  
"pharmacist care" includes the following: 427

(1) Interpreting prescriptions; 428

(2) Dispensing drugs and drug therapy related devices; 429

(3) Compounding drugs; 430

(4) Counseling individuals with regard to their drug 431  
therapy, recommending drug therapy related devices, and 432  
assisting in the selection of drugs and appliances for treatment 433  
of common diseases and injuries and providing instruction in the 434  
proper use of the drugs and appliances; 435

(5) Performing drug regimen reviews with individuals by 436  
discussing all of the drugs that the individual is taking and 437



explaining the interactions of the drugs;	438
(6) Performing drug utilization reviews with licensed health professionals authorized to prescribe drugs when the pharmacist determines that an individual with a prescription has a drug regimen that warrants additional discussion with the prescriber;	439 440 441 442 443
(7) Advising an individual and the health care professionals treating an individual with regard to the individual's drug therapy;	444 445 446
(8) Acting pursuant to a consult agreement, if an agreement has been established;	447 448
(9) Engaging in the administration of immunizations to the extent authorized by section 4729.41 of the Revised Code;	449 450
(10) Engaging in the administration of drugs to the extent authorized by section 4729.45 of the Revised Code.	451 452
(C) "Compounding" means the preparation, mixing, assembling, packaging, and labeling of one or more drugs in any of the following circumstances:	453 454 455
(1) Pursuant to a prescription issued by a licensed health professional authorized to prescribe drugs;	456 457
(2) Pursuant to the modification of a prescription made in accordance with a consult agreement;	458 459
(3) As an incident to research, teaching activities, or chemical analysis;	460 461
(4) In anticipation of orders for drugs pursuant to prescriptions, based on routine, regularly observed dispensing patterns;	462 463 464

(5) Pursuant to a request made by a licensed health professional authorized to prescribe drugs for a drug that is to be used by the professional for the purpose of direct administration to patients in the course of the professional's practice, if all of the following apply:

(a) At the time the request is made, the drug is not commercially available regardless of the reason that the drug is not available, including the absence of a manufacturer for the drug or the lack of a readily available supply of the drug from a manufacturer.

(b) A limited quantity of the drug is compounded and provided to the professional.

(c) The drug is compounded and provided to the professional as an occasional exception to the normal practice of dispensing drugs pursuant to patient-specific prescriptions.

(D) "Consult agreement" means an agreement that has been entered into under section 4729.39 of the Revised Code.

(E) "Drug" means:

(1) Any article recognized in the United States pharmacopoeia and national formulary, or any supplement to them, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals;

(2) Any other article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans or animals;

(3) Any article, other than food, intended to affect the structure or any function of the body of humans or animals;

(4) Any article intended for use as a component of any

article specified in division (E) (1), (2), or (3) of this 493  
section; but does not include devices or their components, 494  
parts, or accessories. 495

"Drug" does not include "hemp" or a "hemp product" as 496  
those terms are defined in section 928.01 of the Revised Code. 497

(F) "Dangerous drug" means any of the following: 498

(1) Any drug to which either of the following applies: 499

(a) Under the "Federal Food, Drug, and Cosmetic Act," 52 500  
Stat. 1040 (1938), 21 U.S.C.A. 301, as amended, the drug is 501  
required to bear a label containing the legend "Caution: Federal 502  
law prohibits dispensing without prescription" or "Caution: 503  
Federal law restricts this drug to use by or on the order of a 504  
licensed veterinarian" or any similar restrictive statement, or 505  
the drug may be dispensed only upon a prescription; 506

(b) Under Chapter 3715. or 3719. of the Revised Code, the 507  
drug may be dispensed only upon a prescription. 508

(2) Any drug that contains a schedule V controlled 509  
substance and that is exempt from Chapter 3719. of the Revised 510  
Code or to which that chapter does not apply; 511

(3) Any drug intended for administration by injection into 512  
the human body other than through a natural orifice of the human 513  
body; 514

(4) Any drug that is a biological product, as defined in 515  
section 3715.01 of the Revised Code. 516

(G) "Federal drug abuse control laws" has the same meaning 517  
as in section 3719.01 of the Revised Code. 518

(H) "Prescription" means all of the following: 519

(1) A written, electronic, or oral order for drugs or combinations or mixtures of drugs to be used by a particular individual or for treating a particular animal, issued by a licensed health professional authorized to prescribe drugs;

(2) For purposes of sections 2925.61, 4723.484, 4730.434, and 4731.94 of the Revised Code, a written, electronic, or oral order for ~~naloxone~~ an overdose reversal drug issued to and in the name of a family member, friend, or other individual in a position to assist an individual who there is reason to believe is at risk of experiencing an opioid-related overdose.

(3) For purposes of section 4729.44 of the Revised Code, a written, electronic, or oral order for ~~naloxone~~ an overdose reversal drug issued to and in the name of either of the following:

(a) An individual who there is reason to believe is at risk of experiencing an opioid-related overdose;

(b) A family member, friend, or other individual in a position to assist an individual who there is reason to believe is at risk of experiencing an opioid-related overdose.

(4) For purposes of sections 4723.4810, 4729.282, 4730.432, and 4731.93 of the Revised Code, a written, electronic, or oral order for a drug to treat chlamydia, gonorrhea, or trichomoniasis issued to and in the name of a patient who is not the intended user of the drug but is the sexual partner of the intended user;

(5) For purposes of sections 3313.7110, 3313.7111, 3314.143, 3326.28, 3328.29, 4723.483, 4729.88, 4730.433, 4731.96, and 5101.76 of the Revised Code, a written, electronic, or oral order for an epinephrine autoinjector issued to and in

the name of a school, school district, or camp; 549

(6) For purposes of Chapter 3728. and sections 4723.483, 550  
4729.88, 4730.433, and 4731.96 of the Revised Code, a written, 551  
electronic, or oral order for an epinephrine autoinjector issued 552  
to and in the name of a qualified entity, as defined in section 553  
3728.01 of the Revised Code; 554

(7) For purposes of sections 3313.7115, 3313.7116, 555  
3314.147, 3326.60, 3328.38, 4723.4811, 4730.437, 4731.92, and 556  
5101.78 of the Revised Code, a written, electronic, or oral 557  
order for injectable or nasally administered glucagon in the 558  
name of a school, school district, or camp. 559

(I) "Licensed health professional authorized to prescribe 560  
drugs" or "prescriber" means an individual who is authorized by 561  
law to prescribe drugs or dangerous drugs or drug therapy 562  
related devices in the course of the individual's professional 563  
practice, including only the following: 564

(1) A dentist licensed under Chapter 4715. of the Revised 565  
Code; 566

(2) A clinical nurse specialist, certified nurse-midwife, 567  
or certified nurse practitioner who holds a current, valid 568  
license issued under Chapter 4723. of the Revised Code to 569  
practice nursing as an advanced practice registered nurse; 570

(3) A certified registered nurse anesthetist who holds a 571  
current, valid license issued under Chapter 4723. of the Revised 572  
Code to practice nursing as an advanced practice registered 573  
nurse, but only to the extent of the nurse's authority under 574  
sections 4723.43 and 4723.434 of the Revised Code; 575

(4) An optometrist licensed under Chapter 4725. of the 576

Revised Code to practice optometry under a therapeutic	577
pharmaceutical agents certificate;	578
(5) A physician authorized under Chapter 4731. of the	579
Revised Code to practice medicine and surgery, osteopathic	580
medicine and surgery, or podiatric medicine and surgery;	581
(6) A physician assistant who holds a license to practice	582
as a physician assistant issued under Chapter 4730. of the	583
Revised Code, holds a valid prescriber number issued by the	584
state medical board, and has been granted physician-delegated	585
prescriptive authority;	586
(7) A veterinarian licensed under Chapter 4741. of the	587
Revised Code.	588
(J) "Sale" or "sell" includes any transaction made by any	589
person, whether as principal proprietor, agent, or employee, to	590
do or offer to do any of the following: deliver, distribute,	591
broker, exchange, gift or otherwise give away, or transfer,	592
whether the transfer is by passage of title, physical movement,	593
or both.	594
(K) "Wholesale sale" and "sale at wholesale" mean any sale	595
in which the purpose of the purchaser is to resell the article	596
purchased or received by the purchaser.	597
(L) "Retail sale" and "sale at retail" mean any sale other	598
than a wholesale sale or sale at wholesale.	599
(M) "Retail seller" means any person that sells any	600
dangerous drug to consumers without assuming control over and	601
responsibility for its administration. Mere advice or	602
instructions regarding administration do not constitute control	603
or establish responsibility.	604

(N) "Price information" means the price charged for a prescription for a particular drug product and, in an easily understandable manner, all of the following:

(1) The proprietary name of the drug product;

(2) The established (generic) name of the drug product;

(3) The strength of the drug product if the product contains a single active ingredient or if the drug product contains more than one active ingredient and a relevant strength can be associated with the product without indicating each active ingredient. The established name and quantity of each active ingredient are required if such a relevant strength cannot be so associated with a drug product containing more than one ingredient.

(4) The dosage form;

(5) The price charged for a specific quantity of the drug product. The stated price shall include all charges to the consumer, including, but not limited to, the cost of the drug product, professional fees, handling fees, if any, and a statement identifying professional services routinely furnished by the pharmacy. Any mailing fees and delivery fees may be stated separately without repetition. The information shall not be false or misleading.

(O) "Wholesale distributor of dangerous drugs" or "wholesale distributor" means a person engaged in the sale of dangerous drugs at wholesale and includes any agent or employee of such a person authorized by the person to engage in the sale of dangerous drugs at wholesale.

(P) "Manufacturer of dangerous drugs" or "manufacturer"

means a person, other than a pharmacist or prescriber, who 633  
manufactures dangerous drugs and who is engaged in the sale of 634  
those dangerous drugs. 635

(Q) "Terminal distributor of dangerous drugs" or "terminal 636  
distributor" means a person who is engaged in the sale of 637  
dangerous drugs at retail, or any person, other than a 638  
manufacturer, repackager, outsourcing facility, third-party 639  
logistics provider, wholesale distributor, or pharmacist, who 640  
has possession, custody, or control of dangerous drugs for any 641  
purpose other than for that person's own use and consumption. 642  
"Terminal distributor" includes pharmacies, hospitals, nursing 643  
homes, and laboratories and all other persons who procure 644  
dangerous drugs for sale or other distribution by or under the 645  
supervision of a pharmacist, licensed health professional 646  
authorized to prescribe drugs, or other person authorized by the 647  
state board of pharmacy. 648

(R) "Promote to the public" means disseminating a 649  
representation to the public in any manner or by any means, 650  
other than by labeling, for the purpose of inducing, or that is 651  
likely to induce, directly or indirectly, the purchase of a 652  
dangerous drug at retail. 653

(S) "Person" includes any individual, partnership, 654  
association, limited liability company, or corporation, the 655  
state, any political subdivision of the state, and any district, 656  
department, or agency of the state or its political 657  
subdivisions. 658

(T)(1) "Animal shelter" means a facility operated by a 659  
humane society or any society organized under Chapter 1717. of 660  
the Revised Code or a dog pound operated pursuant to Chapter 661  
955. of the Revised Code. 662



(2) "County dog warden" means a dog warden or deputy dog warden appointed or employed under section 955.12 of the Revised Code. 663  
664  
665

(U) "Food" has the same meaning as in section 3715.01 of the Revised Code. 666  
667

(V) "Pain management clinic" has the same meaning as in section 4731.054 of the Revised Code. 668  
669

(W) "Investigational drug or product" means a drug or product that has successfully completed phase one of the United States food and drug administration clinical trials and remains under clinical trial, but has not been approved for general use by the United States food and drug administration. 670  
671  
672  
673  
674  
"Investigational drug or product" does not include controlled substances in schedule I, as defined in section 3719.01 of the Revised Code. 675  
676  
677

(X) "Product," when used in reference to an investigational drug or product, means a biological product, other than a drug, that is made from a natural human, animal, or microorganism source and is intended to treat a disease or medical condition. 678  
679  
680  
681  
682

(Y) "Third-party logistics provider" means a person that provides or coordinates warehousing or other logistics services pertaining to dangerous drugs including distribution, on behalf of a manufacturer, wholesale distributor, or terminal distributor of dangerous drugs, but does not take ownership of the drugs or have responsibility to direct the sale or disposition of the drugs. 683  
684  
685  
686  
687  
688  
689

(Z) "Repackager of dangerous drugs" or "repackager" means a person that repacks and relabels dangerous drugs for sale or 690  
691

distribution. 692

(AA) "Outsourcing facility" means a facility that is 693  
engaged in the compounding and sale of sterile drugs and is 694  
registered as an outsourcing facility with the United States 695  
food and drug administration. 696

(BB) "Laboratory" means a laboratory licensed under this 697  
chapter as a terminal distributor of dangerous drugs and 698  
entrusted to have custody of any of the following drugs and to 699  
use the drugs for scientific and clinical purposes and for 700  
purposes of instruction: dangerous drugs that are not controlled 701  
substances, as defined in section 3719.01 of the Revised Code; 702  
dangerous drugs that are controlled substances, as defined in 703  
that section; and controlled substances in schedule I, as 704  
defined in that section. 705

(CC) "Overdose reversal drug" means both of the following: 706

(1) Naloxone; 707

(2) Any other drug that the state board of pharmacy, 708  
through rules adopted in accordance with Chapter 119. of the 709  
Revised Code, designates as a drug that is approved by the 710  
federal food and drug administration for the reversal of a known 711  
or suspected opioid-related overdose. 712

**Sec. 4729.29.** Divisions (A) and (B) of section 4729.01 713  
and section 4729.28 of the Revised Code do not do any of the 714  
following: 715

(A) Apply to a licensed health professional authorized to 716  
prescribe drugs who is acting within the prescriber's scope of 717  
professional practice; 718

(B) Prevent a prescriber from personally furnishing the 719

prescriber's patients with drugs, within the prescriber's scope 720  
of professional practice, that seem proper to the prescriber, as 721  
long as the drugs are furnished in accordance with section 722  
4729.291 of the Revised Code; 723

(C) Apply to an individual who personally furnishes a 724  
supply of ~~naloxone~~ overdose reversal drugs under authority 725  
conferred under section 4723.485, 4730.435, or 4731.941 of the 726  
Revised Code or prevent that individual from personally 727  
furnishing the supply of ~~naloxone~~ overdose reversal drugs in 728  
accordance with a protocol established under section 4723.485, 729  
4730.435, or 4731.941 of the Revised Code; 730

(D) Apply to the sale of oxygen, the sale of peritoneal 731  
dialysis solutions, or the sale of drugs that are not dangerous 732  
drugs by a retail dealer, in original packages when labeled as 733  
required by the "Federal Food, Drug, and Cosmetic Act," 52 Stat. 734  
1040 (1938), 21 U.S.C.A. 301, as amended. 735

**Sec. 4729.44.** (A) As used in this section: 736

(1) "Board of health" means a board of health of a city or 737  
general health district or an authority having the duties of a 738  
board of health under section 3709.05 of the Revised Code. 739

(2) "Physician" means an individual authorized under 740  
Chapter 4731. of the Revised Code to practice medicine and 741  
surgery, osteopathic medicine and surgery, or podiatric medicine 742  
and surgery. 743

(B) If use of the protocol developed pursuant to rules 744  
adopted under division (G) of this section has been authorized 745  
under section 3707.56 or 4731.942 of the Revised Code, a 746  
pharmacist or pharmacy intern may dispense ~~naloxone~~ overdose 747  
reversal drugs without a prescription to either of the following 748

in accordance with that protocol: 749

(1) An individual who there is reason to believe is 750  
 experiencing or at risk of experiencing an opioid-related 751  
 overdose; 752

(2) A family member, friend, or other individual in a 753  
 position to assist an individual who there is reason to believe 754  
 is at risk of experiencing an opioid-related overdose. 755

(C) A pharmacist or pharmacy intern who dispenses ~~naloxone~~ 756  
overdose reversal drugs under this section shall instruct the 757  
 individual to whom ~~naloxone is the drugs are~~ dispensed to summon 758  
 emergency services as soon as practicable either before or after 759  
 administering ~~naloxone~~ the drugs. 760

(D) A pharmacist may document on a prescription form the 761  
 dispensing of ~~naloxone~~ overdose reversal drugs by the pharmacist 762  
 or a pharmacy intern supervised by the pharmacist. The form may 763  
 be assigned a number for record-keeping purposes. 764

(E) This section does not affect the authority of a 765  
 pharmacist or pharmacy intern to fill or refill a prescription 766  
 for ~~naloxone~~ overdose reversal drugs. 767

(F) A board of health that in good faith authorizes a 768  
 pharmacist or pharmacy intern to dispense ~~naloxone~~ overdose 769  
reversal drugs without a prescription in accordance with a 770  
 protocol developed pursuant to rules adopted under division (G) 771  
 of this section is not liable for or subject to any of the 772  
 following for any action or omission of the individual to whom 773  
 the ~~naloxone is~~ drugs are dispensed: damages in any civil 774  
 action, prosecution in any criminal proceeding, or professional 775  
 disciplinary action. 776

A physician who in good faith authorizes a pharmacist or pharmacy intern to dispense ~~naloxone~~ overdose reversal drugs without a prescription in accordance with a protocol developed pursuant to rules adopted under division (G) of this section is not liable for or subject to any of the following for any action or omission of the individual to whom the ~~naloxone is~~ drugs are dispensed: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.

A pharmacist or pharmacy intern authorized under this section to dispense ~~naloxone~~ overdose reversal drugs without a prescription who does so in good faith is not liable for or subject to any of the following for any action or omission of the individual to whom the ~~naloxone is~~ drugs are dispensed: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.

(G) The state board of pharmacy shall, after consulting with the department of health and state medical board, adopt rules to implement this section. The rules shall specify a protocol under which pharmacists or pharmacy interns may dispense ~~naloxone~~ overdose reversal drugs without a prescription.

All rules adopted under this section shall be adopted in accordance with Chapter 119. of the Revised Code.

(H) (1) The state board of pharmacy shall develop a program to educate all of the following about the authority of a pharmacist or pharmacy intern to dispense ~~naloxone~~ overdose reversal drugs without a prescription:

(a) Holders of licenses issued under this chapter that engage in the sale or dispensing of ~~naloxone~~ overdose reversal

drugs pursuant to this section; 806

(b) Registered pharmacy technicians, certified pharmacy technicians, and pharmacy technician trainees registered under this chapter who engage in the sale of ~~naloxone overdose~~ reversal drugs pursuant to this section; 807  
808  
809  
810

(c) Individuals who are not licensed or registered under this chapter but are employed by license holders described in division (H) (1) (a) of this section. 811  
812  
813

(2) As part of the program, the board also shall educate the license holders, pharmacy technicians, and employees described in division (H) (1) of this section about maintaining an adequate supply of ~~naloxone overdose reversal drugs~~ and methods for determining a pharmacy's stock of ~~the drug~~ such drugs. 814  
815  
816  
817  
818  
819

(3) The board may use its web site to share information under the program. 820  
821

**Sec. 4729.51.** (A) No person other than a licensed manufacturer of dangerous drugs, outsourcing facility, third-party logistics provider, repackager of dangerous drugs, or wholesale distributor of dangerous drugs shall possess for sale, sell, distribute, or deliver, at wholesale, dangerous drugs or investigational drugs or products, except as follows: 822  
823  
824  
825  
826  
827

(1) A licensed terminal distributor of dangerous drugs that is a pharmacy may make occasional sales of dangerous drugs or investigational drugs or products at wholesale. 828  
829  
830

(2) A licensed terminal distributor of dangerous drugs having more than one licensed location may transfer or deliver dangerous drugs from one licensed location to another licensed 831  
832  
833

location owned by the terminal distributor if the license issued 834  
for each location is in effect at the time of the transfer or 835  
delivery. 836

(3) A licensed terminal distributor of dangerous drugs 837  
that is not a pharmacy may make occasional sales of the 838  
following at wholesale: 839

(a) ~~Naloxone~~ Overdose reversal drugs; 840

(b) Dangerous drugs if the drugs being sold are in 841  
shortage, as defined in rules adopted under section 4729.26 of 842  
the Revised Code; 843

(c) Dangerous drugs other than those described in 844  
divisions (A) (3) (a) and (b) of this section or investigational 845  
drugs or products if authorized by rules adopted under section 846  
4729.26 of the Revised Code. 847

(B) No licensed manufacturer, outsourcing facility, third- 848  
party logistics provider, repackager, or wholesale distributor 849  
shall possess for sale, sell, or distribute, at wholesale, 850  
dangerous drugs or investigational drugs or products to any 851  
person other than the following: 852

(1) Subject to division (D) of this section, a licensed 853  
terminal distributor of dangerous drugs; 854

(2) Subject to division (C) of this section, any person 855  
exempt from licensure as a terminal distributor of dangerous 856  
drugs under section 4729.541 of the Revised Code; 857

(3) A licensed manufacturer, outsourcing facility, third- 858  
party logistics provider, repackager, or wholesale distributor; 859

(4) A terminal distributor, manufacturer, outsourcing 860  
facility, third-party logistics provider, repackager, or 861

wholesale distributor that is located in another state, is not 862  
engaged in the sale of dangerous drugs within this state, and is 863  
actively licensed to engage in the sale of dangerous drugs by 864  
the state in which the distributor conducts business. 865

(C) No licensed manufacturer, outsourcing facility, third- 866  
party logistics provider, repackager, or wholesale distributor 867  
shall possess for sale, sell, or distribute, at wholesale, 868  
dangerous drugs or investigational drugs or products to either 869  
of the following: 870

(1) A prescriber who is employed by either of the 871  
following: 872

(a) A pain management clinic that is not licensed as a 873  
terminal distributor of dangerous drugs with a pain management 874  
clinic classification issued under section 4729.552 of the 875  
Revised Code; 876

(b) A facility, clinic, or other location that provides 877  
office-based opioid treatment but is not licensed as a terminal 878  
distributor of dangerous drugs with an office-based opioid 879  
treatment classification issued under section 4729.553 of the 880  
Revised Code if such a license is required by that section. 881

(2) A business entity described in division (A) (2) or (3) 882  
of section 4729.541 of the Revised Code that is, or is 883  
operating, either of the following: 884

(a) A pain management clinic without a license as a 885  
terminal distributor of dangerous drugs with a pain management 886  
clinic classification issued under section 4729.552 of the 887  
Revised Code; 888

(b) A facility, clinic, or other location that provides 889



office-based opioid treatment without a license as a terminal distributor of dangerous drugs with an office-based opioid treatment classification issued under section 4729.553 of the Revised Code if such a license is required by that section.

(D) No licensed manufacturer, outsourcing facility, third-party logistics provider, repackager, or wholesale distributor shall possess dangerous drugs or investigational drugs or products for sale at wholesale, or sell or distribute such drugs at wholesale, to a licensed terminal distributor of dangerous drugs, except as follows:

(1) In the case of a terminal distributor with a category II license, only dangerous drugs in category II, as defined in division (A) (1) of section 4729.54 of the Revised Code;

(2) In the case of a terminal distributor with a category III license, dangerous drugs in category II and category III, as defined in divisions (A) (1) and (2) of section 4729.54 of the Revised Code;

(3) In the case of a terminal distributor with a limited category II or III license, only the dangerous drugs specified in the license.

(E) (1) Except as provided in division (E) (2) of this section, no person shall do any of the following:

(a) Sell or distribute, at retail, dangerous drugs;

(b) Possess for sale, at retail, dangerous drugs;

(c) Possess dangerous drugs.

(2) (a) Divisions (E) (1) (a), (b), and (c) of this section do not apply to any of the following:

(i) A licensed terminal distributor of dangerous drugs;	917
(ii) A person who possesses, or possesses for sale or sells, at retail, a dangerous drug in accordance with Chapters 3719., 4715., 4723., 4725., 4729., 4730., 4731., and 4741. of the Revised Code;	918 919 920 921
(iii) Any of the persons identified in divisions (A) (1) to (5) and (13) of section 4729.541 of the Revised Code, but only to the extent specified in that section.	922 923 924
(b) Division (E) (1) (c) of this section does not apply to any of the following:	925 926
(i) A licensed manufacturer, outsourcing facility, third- party logistics provider, repackager, or wholesale distributor;	927 928
(ii) Any of the persons identified in divisions (A) (6) to (12) of section 4729.541 of the Revised Code, but only to the extent specified in that section.	929 930 931
(F) No licensed terminal distributor of dangerous drugs or person that is exempt from licensure under section 4729.541 of the Revised Code shall purchase dangerous drugs or investigational drugs or products from any person other than a licensed manufacturer, outsourcing facility, third-party logistics provider, repackager, or wholesale distributor, except as follows:	932 933 934 935 936 937 938
(1) A licensed terminal distributor of dangerous drugs or person that is exempt from licensure under section 4729.541 of the Revised Code may make occasional purchases of dangerous drugs or investigational drugs or products that are sold in accordance with division (A) (1) or (3) of this section.	939 940 941 942 943
(2) A licensed terminal distributor of dangerous drugs	944

having more than one licensed location may transfer or deliver 945  
dangerous drugs or investigational drugs or products from one 946  
licensed location to another licensed location if the license 947  
issued for each location is in effect at the time of the 948  
transfer or delivery. 949

(G) No licensed terminal distributor of dangerous drugs 950  
shall engage in the retail sale or other distribution of 951  
dangerous drugs or investigational drugs or products or maintain 952  
possession, custody, or control of dangerous drugs or 953  
investigational drugs or products for any purpose other than the 954  
distributor's personal use or consumption, at any establishment 955  
or place other than that or those described in the license 956  
issued by the state board of pharmacy to such terminal 957  
distributor. 958

(H) Nothing in this section shall be construed to 959  
interfere with the performance of official duties by any law 960  
enforcement official authorized by municipal, county, state, or 961  
federal law to collect samples of any drug, regardless of its 962  
nature or in whose possession it may be. 963

(I) Notwithstanding anything to the contrary in this 964  
section, the board of education of a city, local, exempted 965  
village, or joint vocational school district may distribute 966  
epinephrine autoinjectors for use in accordance with section 967  
3313.7110 of the Revised Code, may distribute inhalers for use 968  
in accordance with section 3313.7113 of the Revised Code, and 969  
may distribute injectable or nasally administered glucagon for 970  
use in accordance with section 3313.7115 of the Revised Code. 971

**Sec. 4729.511.** (A) As used in this section, "~~naloxone~~ 972  
overdose reversal drug distributor" means either of the 973  
following: 974

(1) A wholesale distributor of dangerous drugs;	975
(2) A terminal distributor of dangerous drugs that supplies <del>naloxone-overdose reversal drugs</del> to any entity under division (B) (1) of this section.	976 977 978
(B) (1) <del>A naloxone</del> <u>An overdose reversal drug distributor</u> shall prioritize the sale, distribution, and delivery of <del>naloxone-overdose reversal drugs</del> to all of the following:	979 980 981
(a) A children's hospital, as defined in section 3727.01 of the Revised Code;	982 983
(b) A hospital, as defined in section 3727.01 of the Revised Code;	984 985
(c) An emergency medical service organization, as defined in section 4765.01 of the Revised Code;	986 987
(d) A facility that is operated as an urgent care center.	988
(2) The order in which the entities are listed in division (B) (1) of this section does not establish levels of priority among the listed entities.	989 990 991
(C) <del>A naloxone</del> <u>An overdose reversal drug distributor</u> who in good faith complies with division (B) of this section is not liable for or subject to any of the following for an act or omission arising from that compliance: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	992 993 994 995 996 997
<b>Sec. 4729.514.</b> (A) As used in this section, "service entity" means a public or private entity that may provide services to or interact with individuals who there is reason to believe may be at risk of experiencing an opioid-related overdose. "Service entity" includes a church or other place of	998 999 1000 1001 1002

worship, college or university, school, library, health 1003  
department operated by the board of health of a city or general 1004  
health district, community addiction services provider, court, 1005  
probation department, halfway house, prison, jail, community 1006  
residential center, homeless shelter, or similar entity. 1007

(B) A service entity may procure and maintain ~~naloxone~~ 1008  
overdose reversal drugs for either or both of the following 1009  
purposes: 1010

(1) To use in emergency situations; 1011

(2) To permit an employee, volunteer, or contractor of the 1012  
service entity to personally furnish a supply of ~~naloxone~~ 1013  
overdose reversal drugs pursuant to a protocol established under 1014  
section 3707.561, 4723.485, 4730.435, or 4731.941 of the Revised 1015  
Code. 1016

(C) A service entity or an employee, volunteer, or 1017  
contractor of a service entity is not liable for or subject to 1018  
any of the following for injury, death, or loss to person or 1019  
property that allegedly arises from an act or omission 1020  
associated with procuring, maintaining, accessing, using, or 1021  
personally furnishing ~~naloxone~~ overdose reversal drugs under 1022  
this section, unless the act or omission constitutes willful or 1023  
wanton misconduct: damages in any civil action, prosecution in 1024  
any criminal proceeding, or professional disciplinary action. 1025

This section does not eliminate, limit, or reduce any 1026  
other immunity or defense that a service entity or an employee, 1027  
volunteer, or contractor of a service entity may be entitled to 1028  
under Chapter 2305. or any other provision of the Revised Code 1029  
or under the common law of this state. 1030

**Sec. 4729.515.** (A) In accordance with divisions (B) and 1031

(C) of this section, a terminal distributor of dangerous drugs 1032  
may acquire and maintain a supply of ~~naloxone overdose reversal~~ 1033  
drugs for use in emergency situations and for distribution 1034  
through an automated mechanism. The ~~naloxone overdose reversal~~ 1035  
drugs may be maintained at a location other than the location 1036  
licensed as a terminal distributor of dangerous drugs. 1037

(B) In the case of ~~naloxone overdose reversal drugs~~ for 1038  
use in emergency situations, a terminal distributor of dangerous 1039  
drugs shall do all of the following: 1040

(1) Provide instructions regarding the emergency 1041  
administration of ~~naloxone overdose reversal drugs~~ to any 1042  
individual who accesses ~~the naloxone~~ such drugs, including a 1043  
specific instruction to summon emergency services as set forth 1044  
in division (D) of this section; 1045

(2) Specify a process to be used to notify the terminal 1046  
distributor that ~~the naloxone an overdose reversal drug~~ has been 1047  
accessed within a reasonable time of its being accessed; 1048

(3) Maintain ~~the naloxone overdose reversal drugs~~ in 1049  
accordance with the manufacturer's or distributor's 1050  
instructions. 1051

(C) In the case of ~~naloxone overdose reversal drugs~~ for 1052  
distribution through an automated mechanism, a terminal 1053  
distributor of dangerous drugs shall comply with standards and 1054  
procedures specified in rules adopted under division (F) of this 1055  
section. 1056

(D) (1) Notwithstanding any conflicting provision of the 1057  
Revised Code, both of the following apply: 1058

(a) Any individual may access ~~naloxone overdose reversal~~ 1059  
drugs

drugs maintained as provided in division (B) of this section and 1060  
may administer ~~it~~ the drugs to an individual who there is reason 1061  
to believe is experiencing an opioid-related overdose. 1062

(b) Any individual may receive ~~naloxone-overdose reversal~~ 1063  
drugs distributed through an automated system as provided in 1064  
division (C) of this section and may administer ~~it~~ the drugs to 1065  
an individual who there is reason to believe is experiencing an 1066  
opioid-related overdose. 1067

(2) An individual who administers ~~naloxone-overdose~~ 1068  
reversal drugs as authorized by this section shall make a good 1069  
faith effort to activate or have another individual activate an 1070  
emergency medical services system as soon as possible, except 1071  
that this requirement does not apply if the individual 1072  
administering the ~~naloxone~~ drugs is doing so as part of an 1073  
emergency medical services system or at a hospital, as defined 1074  
in section 3727.01 of the Revised Code. 1075

(E) An individual is not liable for or subject to any of 1076  
the following for injury, death, or loss to person or property 1077  
that allegedly arises from an act or omission associated with 1078  
any action authorized by this section, unless the act or 1079  
omission constitutes willful or wanton misconduct: damages in 1080  
any civil action, prosecution in any criminal proceeding, or 1081  
professional disciplinary action. 1082

(F) The state board of pharmacy shall adopt rules 1083  
establishing standards and procedures applicable to the 1084  
distribution of ~~naloxone-overdose reversal drugs~~ through an 1085  
automated mechanism. The rules shall be adopted in accordance 1086  
with Chapter 119. of the Revised Code. 1087

**Sec. 4729.541.** (A) Except as provided in divisions (B) to 1088

(D) of this section, all of the following are exempt from	1089
licensure as a terminal distributor of dangerous drugs:	1090
(1) A licensed health professional authorized to prescribe	1091
drugs;	1092
(2) A business entity that is a corporation formed under	1093
division (B) of section 1701.03 of the Revised Code, a limited	1094
liability company formed under Chapter 1705. or 1706. of the	1095
Revised Code, or a professional association formed under Chapter	1096
1785. of the Revised Code if the entity has a sole shareholder	1097
who is a prescriber and is authorized to provide the	1098
professional services being offered by the entity;	1099
(3) A business entity that is a corporation formed under	1100
division (B) of section 1701.03 of the Revised Code, a limited	1101
liability company formed under Chapter 1705. or 1706. of the	1102
Revised Code, a partnership or a limited liability partnership	1103
formed under Chapter 1775. of the Revised Code, or a	1104
professional association formed under Chapter 1785. of the	1105
Revised Code, if, to be a shareholder, member, or partner, an	1106
individual is required to be licensed, certified, or otherwise	1107
legally authorized under Title XLVII of the Revised Code to	1108
perform the professional service provided by the entity and each	1109
such individual is a prescriber;	1110
(4) An individual who holds a current license,	1111
certificate, or registration issued under Title XLVII of the	1112
Revised Code and has been certified to conduct diabetes	1113
education by a national certifying body specified in rules	1114
adopted by the state board of pharmacy under section 4729.68 of	1115
the Revised Code, but only with respect to insulin that will be	1116
used for the purpose of diabetes education and only if diabetes	1117
education is within the individual's scope of practice under	1118



statutes and rules regulating the individual's profession; 1119

(5) An individual who holds a valid certificate issued by 1120  
a nationally recognized S.C.U.B.A. diving certifying 1121  
organization approved by the state board of pharmacy under rules 1122  
adopted by the board, but only with respect to medical oxygen 1123  
that will be used for the purpose of emergency care or treatment 1124  
at the scene of a diving emergency; 1125

(6) With respect to epinephrine autoinjectors that may be 1126  
possessed under section 3313.7110, 3313.7111, 3314.143, 3326.28, 1127  
or 3328.29 of the Revised Code, any of the following: the board 1128  
of education of a city, local, exempted village, or joint 1129  
vocational school district; a chartered or nonchartered 1130  
nonpublic school; a community school established under Chapter 1131  
3314. of the Revised Code; a STEM school established under 1132  
Chapter 3326. of the Revised Code; or a college-preparatory 1133  
boarding school established under Chapter 3328. of the Revised 1134  
Code; 1135

(7) With respect to epinephrine autoinjectors that may be 1136  
possessed under section 5101.76 of the Revised Code, any of the 1137  
following: a residential camp, as defined in section 2151.011 of 1138  
the Revised Code; a child day camp, as defined in section 1139  
5104.01 of the Revised Code; or a child day camp operated by any 1140  
county, township, municipal corporation, township park district 1141  
created under section 511.18 of the Revised Code, park district 1142  
created under section 1545.04 of the Revised Code, or joint 1143  
recreation district established under section 755.14 of the 1144  
Revised Code; 1145

(8) With respect to epinephrine autoinjectors that may be 1146  
possessed under Chapter 3728. of the Revised Code, a qualified 1147  
entity, as defined in section 3728.01 of the Revised Code; 1148

(9) With respect to inhalers that may be possessed under 1149  
section 3313.7113, 3313.7114, 3314.144, 3326.30, or 3328.30 of 1150  
the Revised Code, any of the following: the board of education 1151  
of a city, local, exempted village, or joint vocational school 1152  
district; a chartered or nonchartered nonpublic school; a 1153  
community school established under Chapter 3314. of the Revised 1154  
Code; a STEM school established under Chapter 3326. of the 1155  
Revised Code; or a college-preparatory boarding school 1156  
established under Chapter 3328. of the Revised Code; 1157

(10) With respect to inhalers that may be possessed under 1158  
section 5101.77 of the Revised Code, any of the following: a 1159  
residential camp, as defined in section 2151.011 of the Revised 1160  
Code; a child day camp, as defined in section 5104.01 of the 1161  
Revised Code; or a child day camp operated by any county, 1162  
township, municipal corporation, township park district created 1163  
under section 511.18 of the Revised Code, park district created 1164  
under section 1545.04 of the Revised Code, or joint recreation 1165  
district established under section 755.14 of the Revised Code; 1166

(11) With respect to ~~naloxone overdose reversal drugs~~ that 1167  
may be possessed under section 2925.61 of the Revised Code, a 1168  
law enforcement agency and its peace officers; 1169

(12) With respect to ~~naloxone overdose reversal drugs~~ that 1170  
may be possessed under section 4729.514 of the Revised Code for 1171  
use in emergency situations or for personally furnishing 1172  
supplies of ~~naloxone overdose reversal drugs~~, a service entity, 1173  
as defined in that section; 1174

(13) A facility that is owned and operated by the United 1175  
States department of defense, the United States department of 1176  
veterans affairs, or any other federal agency; 1177

(14) With respect to injectable or nasally administered 1178  
glucagon that may be possessed under sections 3313.7115, 1179  
3313.7116, 3314.147, 3326.60, and 3328.38 of the Revised Code, 1180  
any of the following: the board of education of a city, local, 1181  
exempted village, or joint vocational school district; a 1182  
chartered or nonchartered nonpublic school; a community school 1183  
established under Chapter 3314. of the Revised Code; a STEM 1184  
school established under Chapter 3326. of the Revised Code; or a 1185  
college-preparatory boarding school established under Chapter 1186  
3328. of the Revised Code; 1187

(15) With respect to injectable or nasally administered 1188  
glucagon that may be possessed under section 5101.78 of the 1189  
Revised Code, any of the following: a residential camp, as 1190  
defined in section 2151.011 of the Revised Code; a child day 1191  
camp, as defined in section 5104.01 of the Revised Code; or a 1192  
child day camp operated by any county, township, municipal 1193  
corporation, township park district created under section 511.18 1194  
of the Revised Code, park district created under section 1545.04 1195  
of the Revised Code, or joint recreation district established 1196  
under section 755.14 of the Revised Code. 1197

(B) If a person described in division (A) of this section 1198  
is a pain management clinic or is operating a pain management 1199  
clinic, the person shall hold a license as a terminal 1200  
distributor of dangerous drugs with a pain management clinic 1201  
classification issued under section 4729.552 of the Revised 1202  
Code. 1203

(C) If a person described in division (A) of this section 1204  
is operating a facility, clinic, or other location described in 1205  
division (B) of section 4729.553 of the Revised Code that must 1206  
hold a category III terminal distributor of dangerous drugs 1207

license with an office-based opioid treatment classification, 1208  
the person shall hold a license with that classification. 1209

(D) Any of the persons described in divisions (A) (1) to 1210  
(12) of this section shall hold a license as a terminal 1211  
distributor of dangerous drugs in order to possess, have custody 1212  
or control of, and distribute any of the following: 1213

(1) Dangerous drugs that are compounded or used for the 1214  
purpose of compounding; 1215

(2) A schedule I, II, III, IV, or V controlled substance, 1216  
as defined in section 3719.01 of the Revised Code. 1217

**Sec. 4730.434.** (A) As used in this section and in 1218  
sections 4730.435 and 4730.436 of the Revised Code, "overdose 1219  
reversal drug" has the same meaning as in section 4729.01 of the 1220  
Revised Code. 1221

(B) Notwithstanding any provision of this chapter or rule 1222  
adopted by the state medical board, a physician assistant who 1223  
holds a valid prescriber number issued by the board and has been 1224  
granted physician-delegated prescriptive authority may 1225  
personally furnish a supply of ~~naloxone~~ overdose reversal drugs, 1226  
or issue a prescription for ~~naloxone~~ such drugs, without having 1227  
examined the individual to whom it may be administered if both 1228  
of the following conditions are met: 1229

(1) The ~~naloxone~~ supply is furnished to, or the 1230  
prescription is issued to and in the name of, a family member, 1231  
friend, or other individual in a position to assist an 1232  
individual who there is reason to believe is at risk of 1233  
experiencing an opioid-related overdose. 1234

(2) The physician assistant instructs the individual 1235

receiving the ~~naloxone~~ supply or prescription to summon 1236  
emergency services as soon as practicable either before or after 1237  
administering ~~naloxone~~ an overdose reversal drug to an 1238  
individual apparently experiencing an opioid-related overdose. 1239

~~(B)~~ (C) A physician assistant who under division ~~(A)~~ (B) 1240  
of this section in good faith furnishes a supply of ~~naloxone~~ 1241  
overdose reversal drugs or issues a prescription for ~~naloxone~~ 1242  
overdose reversal drugs is not liable for or subject to any of 1243  
the following for any action or omission of the individual to 1244  
whom the ~~naloxone~~ is ~~drugs~~ are furnished or the prescription is 1245  
issued: damages in any civil action, prosecution in any criminal 1246  
proceeding, or professional disciplinary action. 1247

**Sec. 4730.435.** (A) (1) A physician assistant who holds a 1248  
valid prescriber number issued by the state medical board, who 1249  
has been granted physician-delegated prescriptive authority, and 1250  
who has established a protocol that meets the requirements of 1251  
division (C) of this section may authorize one or more other 1252  
individuals to personally furnish a supply of ~~naloxone~~ overdose 1253  
reversal drugs pursuant to the protocol to either of the 1254  
following: 1255

(a) An individual who there is reason to believe is 1256  
experiencing or at risk of experiencing an opioid-related 1257  
overdose; 1258

(b) A family member, friend, or other person in a position 1259  
to assist an individual who there is reason to believe is at 1260  
risk of experiencing an opioid-related overdose. 1261

(2) An individual authorized under this section to 1262  
personally furnish ~~naloxone~~ overdose reversal drugs may do so 1263  
without having examined the individual to whom ~~it~~ the drug may 1264

be administered. 1265

(B) An individual authorized by a physician assistant 1266  
under this section may personally furnish ~~naloxone~~ overdose 1267  
reversal drugs to an individual described in division (A) (1) (a) 1268  
or (b) of this section if both of the following conditions are 1269  
met: 1270

(1) The authorized individual complies with the protocol 1271  
established by the authorizing physician assistant, including 1272  
having completed the training required by the protocol. 1273

(2) The authorized individual instructs the individual to 1274  
whom ~~naloxone is~~ overdose reversal drugs are furnished to summon 1275  
emergency services as soon as practicable either before or after 1276  
administering ~~naloxone~~ the drugs. 1277

(C) A protocol established by a physician assistant for 1278  
purposes of this section shall be established in writing and 1279  
include all of the following: 1280

(1) A description of the clinical pharmacology of ~~naloxone~~ 1281  
the overdose reversal drugs specified in the protocol; 1282

(2) Precautions and contraindications concerning 1283  
furnishing ~~naloxone~~ overdose reversal drugs; 1284

(3) Any limitations the physician assistant specifies 1285  
concerning the individuals to whom ~~naloxone~~ overdose reversal 1286  
drugs may be furnished; 1287

(4) The ~~naloxone~~ dosage that may be furnished and any 1288  
variation in the dosage based on circumstances specified in the 1289  
protocol; 1290

(5) Labeling, storage, record keeping, and administrative 1291  
requirements; 1292

(6) Training requirements that must be met before an individual will be authorized to furnish <del>naloxone</del> <u>overdose reversal drugs</u> ;	1293
	1294
	1295
(7) Any instructions or training that the authorized individual must provide to an individual to whom <del>naloxone is</del> <u>overdose reversal drugs are</u> furnished.	1296
	1297
	1298
(D) A physician assistant who in good faith authorizes another individual to personally furnish <del>naloxone</del> <u>overdose reversal drugs</u> in accordance with a protocol established by the physician assistant under this section is not liable for or subject to any of the following for any action or omission of the individual to whom the <del>naloxone is</del> <u>drugs are</u> furnished: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	1299
	1300
	1301
	1302
	1303
	1304
	1305
	1306
An individual authorized under this section to personally furnish <del>naloxone</del> <u>overdose reversal drugs</u> who does so in good faith is not liable for or subject to any of the following for any action or omission of the individual to whom the <del>naloxone is</del> <u>drugs are</u> furnished: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	1307
	1308
	1309
	1310
	1311
	1312
<b>Sec. 4730.436.</b> (A) As used in this section, "service entity" has the same meaning as in section 4729.514 of the Revised Code.	1313
	1314
	1315
(B) A physician assistant who holds a valid prescriber number issued by the state medical board, who has been granted physician-delegated prescriptive authority, and who has established a protocol under division (D) of this section may authorize an individual who is an employee, volunteer, or contractor of a service entity to administer <del>naloxone</del> <u>overdose</u>	1316
	1317
	1318
	1319
	1320
	1321

reversal drugs to an individual who is apparently experiencing 1322  
an opioid-related overdose. 1323

(C) An individual authorized by a physician assistant 1324  
under this section may administer ~~naloxone~~ overdose reversal 1325  
drugs to an individual who is apparently experiencing an opioid- 1326  
related overdose if all of the following conditions are met: 1327

(1) The ~~naloxone~~ overdose reversal drug is obtained from a 1328  
service entity of which the authorized individual is an 1329  
employee, volunteer, or contractor. 1330

(2) The authorized individual complies with the protocol 1331  
established by the authorizing physician assistant. 1332

(3) The authorized individual summons emergency services 1333  
as soon as practicable either before or after administering the 1334  
~~naloxone~~ overdose reversal drug. 1335

(D) A protocol established by a physician assistant for 1336  
purposes of this section must be in writing and include all of 1337  
the following: 1338

(1) A description of the clinical pharmacology of ~~naloxone~~ 1339  
the overdose reversal drugs specified in the protocol; 1340

(2) Precautions and contraindications concerning the 1341  
administration of ~~naloxone~~ overdose reversal drugs; 1342

(3) Any limitations the physician assistant specifies 1343  
concerning the individuals to whom ~~naloxone~~ overdose reversal 1344  
drugs may be administered; 1345

(4) The ~~naloxone~~ dosage that may be administered and any 1346  
variation in the dosage based on circumstances specified in the 1347  
protocol; 1348



(5) Labeling, storage, record keeping, and administrative requirements;	1349
	1350
(6) Training requirements that must be met before an individual can be authorized to administer <del>naloxone</del> <u>overdose reversal drugs</u> .	1351
	1352
	1353
(E) A physician assistant who in good faith authorizes an individual to administer <del>naloxone</del> <u>overdose reversal drugs</u> under this section is not liable for or subject to any of the following for any act or omission of the authorized individual: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	1354
	1355
	1356
	1357
	1358
	1359
A service entity or an employee, volunteer, or contractor of a service entity is not liable for or subject to any of the following for injury, death, or loss to person or property that allegedly arises from an act or omission associated with procuring, maintaining, accessing, or administering <del>naloxone</del> <u>overdose reversal drugs</u> under this section, unless the act or omission constitutes willful or wanton misconduct: damages in any civil action, prosecution in any criminal proceeding, or professional disciplinary action.	1360
	1361
	1362
	1363
	1364
	1365
	1366
	1367
	1368
This section does not eliminate, limit, or reduce any other immunity or defense that a service entity or an employee, volunteer, or contractor of a service entity may be entitled to under Chapter 2305. or any other provision of the Revised Code or under the common law of this state.	1369
	1370
	1371
	1372
	1373
<b>Sec. 4731.94.</b> (A) As used in this section and <u>in</u> sections 4731.941, 4731.942, and 4731.943 of the Revised Code, <del>—</del> <u>"physician"</u> :	1374
	1375
	1376
(1) <u>"Overdose reversal drug"</u> has the same meaning as in	1377

section 4729.01 of the Revised Code. 1378

(2) "Physician" means an individual authorized under this 1379  
chapter to practice medicine and surgery, osteopathic medicine 1380  
and surgery, or podiatric medicine and surgery. 1381

(B) Notwithstanding any provision of this chapter or rule 1382  
adopted by the state medical board, a physician may personally 1383  
furnish a supply of ~~naloxone overdose reversal drugs~~, or issue a 1384  
prescription for ~~naloxone overdose reversal drugs~~, without 1385  
having examined the individual to whom it may be administered if 1386  
both of the following conditions are met: 1387

(1) The ~~naloxone~~ supply is furnished to, or the 1388  
prescription is issued to and in the name of, a family member, 1389  
friend, or other individual in a position to assist an 1390  
individual who there is reason to believe is at risk of 1391  
experiencing an opioid-related overdose. 1392

(2) The physician instructs the individual receiving the 1393  
~~naloxone~~ supply or prescription to summon emergency services as 1394  
soon as practicable either before or after administering ~~the~~ 1395  
~~naloxone~~ an overdose reversal drug to an individual apparently 1396  
experiencing an opioid-related overdose. 1397

(C) A physician who under division (B) of this section in 1398  
good faith furnishes a supply of ~~naloxone overdose reversal~~ 1399  
drugs or issues a prescription for ~~naloxone overdose reversal~~ 1400  
drugs is not liable for or subject to any of the following for 1401  
any act or omission of the individual to whom the ~~naloxone is~~ 1402  
drugs are furnished or the prescription is issued: damages in 1403  
any civil action, prosecution in any criminal proceeding, or 1404  
professional disciplinary action. 1405

**Sec. 4731.941.** (A) (1) A physician who has established a 1406

protocol that meets the requirements of division (C) of this 1407  
section may authorize one or more other individuals to 1408  
personally furnish a supply of ~~naloxone~~ overdose reversal drugs 1409  
pursuant to the protocol to either of the following: 1410

(a) An individual who there is reason to believe is 1411  
experiencing or at risk of experiencing an opioid-related 1412  
overdose; 1413

(b) A family member, friend, or other person in a position 1414  
to assist an individual who there is reason to believe is at 1415  
risk of experiencing an opioid-related overdose. 1416

(2) An individual authorized under this section to 1417  
personally furnish ~~naloxone~~ overdose reversal drugs may do so 1418  
without having examined the individual to whom it may be 1419  
administered. 1420

(B) An individual authorized by a physician under this 1421  
section may personally furnish ~~naloxone~~ overdose reversal drugs 1422  
to an individual described in division (A) (1) (a) or (b) of this 1423  
section if both of the following conditions are met: 1424

(1) The authorized individual complies with the protocol 1425  
established by the authorizing physician, including having 1426  
completed the training required by the protocol. 1427

(2) The authorized individual instructs the individual to 1428  
whom ~~naloxone is~~ overdose reversal drugs are furnished to summon 1429  
emergency services as soon as practicable either before or after 1430  
administering ~~naloxone~~ the drugs. 1431

(C) A protocol established by a physician for purposes of 1432  
this section shall be established in writing and include all of 1433  
the following: 1434

(1) A description of the clinical pharmacology of <del>naloxone</del>	1435
<u>the overdose reversal drugs specified in the protocol;</u>	1436
(2) Precautions and contraindications concerning	1437
<u>furnishing <del>naloxone</del> overdose reversal drugs;</u>	1438
(3) Any limitations the physician specifies concerning the	1439
individuals to whom <del>naloxone</del> <u>overdose reversal drugs</u> may be	1440
furnished;	1441
(4) The <del>naloxone</del> -dosage that may be furnished and any	1442
variation in the dosage based on circumstances specified in the	1443
protocol;	1444
(5) Labeling, storage, record-keeping, and administrative	1445
requirements;	1446
(6) Training requirements that must be met before an	1447
individual will be authorized to furnish <del>naloxone</del> <u>overdose</u>	1448
<u>reversal drugs;</u>	1449
(7) Any instructions or training that the authorized	1450
individual must provide to an individual to whom <del>naloxone is</del>	1451
<u>overdose reversal drugs are</u> furnished.	1452
(D) A physician who in good faith authorizes another	1453
individual to personally furnish <del>naloxone</del> <u>overdose reversal</u>	1454
<u>drugs</u> in accordance with a protocol established by the physician	1455
under this section is not liable for or subject to any of the	1456
following for any action or omission of the individual to whom	1457
the <del>naloxone is</del> <u>drugs are</u> furnished: damages in any civil	1458
action, prosecution in any criminal proceeding, or professional	1459
disciplinary action.	1460
An individual authorized under this section to personally	1461
furnish <del>naloxone</del> <u>overdose reversal drugs</u> who does so in good	1462

faith is not liable for or subject to any of the following for 1463  
any action or omission of the individual to whom the ~~naloxone is~~ 1464  
drugs are furnished: damages in any civil action, prosecution in 1465  
any criminal proceeding, or professional disciplinary action. 1466

**Sec. 4731.942.** A physician may authorize one or more 1467  
pharmacists and any of the pharmacy interns supervised by the 1468  
pharmacist or pharmacists to use the protocol developed pursuant 1469  
to rules adopted under section 4729.44 of the Revised Code for 1470  
the purpose of dispensing ~~naloxone~~overdose reversal drugs under 1471  
section 4729.44 of the Revised Code. 1472

**Sec. 4731.943.** (A) As used in this section, "service 1473  
entity" has the same meaning as in section 4729.514 of the 1474  
Revised Code. 1475

(B) A physician who has established a protocol under 1476  
division (D) of this section may authorize an individual who is 1477  
an employee, volunteer, or contractor of a service entity to 1478  
administer ~~naloxone~~overdose reversal drugs to an individual who 1479  
is apparently experiencing an opioid-related overdose. 1480

(C) An individual authorized by a physician under this 1481  
section may administer ~~naloxone~~overdose reversal drugs to an 1482  
individual who is apparently experiencing an opioid-related 1483  
overdose if all of the following conditions are met: 1484

(1) The ~~naloxone~~overdose reversal drug is obtained from a 1485  
service entity of which the authorized individual is an 1486  
employee, volunteer, or contractor. 1487

(2) The authorized individual complies with the protocol 1488  
established by the authorizing physician. 1489

(3) The authorized individual summons emergency services 1490

as soon as practicable either before or after administering the- 1491  
~~naloxone~~ overdose reversal drug. 1492

(D) A protocol established by a physician for purposes of 1493  
this section must be in writing and include all of the 1494  
following: 1495

(1) A description of the clinical pharmacology of ~~naloxone~~ 1496  
overdose reversal drugs specified in the protocol; 1497

(2) Precautions and contraindications concerning the 1498  
administration of ~~naloxone~~ overdose reversal drugs; 1499

(3) Any limitations the physician specifies concerning the 1500  
individuals to whom ~~naloxone~~ overdose reversal drugs may be 1501  
administered; 1502

(4) The ~~naloxone~~ dosage that may be administered and any 1503  
variation in the dosage based on circumstances specified in the 1504  
protocol; 1505

(5) Labeling, storage, record-keeping, and administrative 1506  
requirements; 1507

(6) Training requirements that must be met before an 1508  
individual can be authorized to administer ~~naloxone~~ overdose 1509  
reversal drugs. 1510

(E) A physician who in good faith authorizes an individual 1511  
to administer ~~naloxone~~ overdose reversal drugs under this 1512  
section is not liable for or subject to any of the following for 1513  
any act or omission of the authorized individual: damages in any 1514  
civil action, prosecution in any criminal proceeding, or 1515  
professional disciplinary action. 1516

A service entity or an employee, volunteer, or contractor 1517  
of a service entity is not liable for or subject to any of the 1518

following for injury, death, or loss to person or property that 1519  
allegedly arises from an act or omission associated with 1520  
procuring, maintaining, accessing, or administering ~~naloxone-~~ 1521  
overdose reversal drugs under this section, unless the act or 1522  
omission constitutes willful or wanton misconduct: damages in 1523  
any civil action, prosecution in any criminal proceeding, or 1524  
professional disciplinary action. 1525

This section does not eliminate, limit, or reduce any 1526  
other immunity or defense that a service entity or an employee, 1527  
volunteer, or contractor of a service entity may be entitled to 1528  
under Chapter 2305. or any other provision of the Revised Code 1529  
or under the common law of this state. 1530

**Sec. 4765.44.** (A) As used in this section, "law 1531  
enforcement agency" ~~has~~ and "overdose reversal drug" have the 1532  
same ~~meaning~~ meanings as in section 2925.61 of the Revised Code. 1533

(B) (1) Upon request of a law enforcement agency as 1534  
described in division (B) (2) of this section, emergency medical 1535  
service personnel and any firefighter or volunteer firefighter 1536  
acting within the course of the firefighting profession shall 1537  
disclose the name and address, if known, of an individual to 1538  
whom the emergency medical ~~services~~ service personnel, 1539  
firefighter, or volunteer firefighter administered ~~naloxone-an~~ 1540  
overdose reversal drug due to an actual or suspected drug 1541  
overdose, unless the emergency medical ~~services~~ service 1542  
personnel, firefighter, or volunteer firefighter reasonably 1543  
believes that the law enforcement agency making the request does 1544  
not have jurisdiction over the place where the ~~naloxone-overdose~~ 1545  
reversal drug was administered. 1546

(2) A law enforcement agency may request a name and 1547  
address of an individual under division (B) (1) of this section 1548

for the purposes of investigation or treatment referral and may 1549  
use a name and address received under that division for either 1550  
or both of those purposes. 1551

**Sec. 4765.45.** (A) If the department of public safety 1552  
collects any of the following information regarding the 1553  
administration of naloxone-overdose reversal drugs, as defined 1554  
in section 4729.01 of the Revised Code, by emergency medical 1555  
service personnel or any firefighter or volunteer firefighter, 1556  
the department of public safety shall report the information for 1557  
the previous month to the department of health on a monthly 1558  
basis and in a manner prescribed by the department of health: 1559

(1) The five-digit postal zip code plus four-digit add-on 1560  
where the naloxone-overdose reversal drug was administered; 1561

(2) The date on which the naloxone-overdose reversal drug 1562  
was administered; 1563

(3) The number of doses administered; 1564

(4) The name of the emergency medical service organization 1565  
or fire department that administered the naloxone-overdose 1566  
reversal drug; 1567

(5) Whether or not an overdose was reversed; 1568

(6) Whether the individual to whom naloxone-the overdose 1569  
reversal drug was administered was taken to a hospital; 1570

(7) If known, the individual's age; 1571

(8) If known, the United States postal zip code in which 1572  
the individual resides. 1573

When reporting to the department of health, the department 1574  
of public safety shall not include any information that 1575



identifies or tends to identify specific individuals to whom 1576  
~~naloxone was~~ overdose reversal drugs were administered. 1577

(B) Each month, the department of health shall compile the 1578  
information received under division (A) of this section, 1579  
organize it by county, and forward it to each board of alcohol, 1580  
drug addiction, and mental health services in this state. 1581

(C) The department of health may adopt rules as necessary 1582  
to implement this section. The rules shall be adopted in 1583  
accordance with Chapter 119. of the Revised Code. 1584

**Sec. 4765.52.** (A) As used in this section, ~~"veterinarian"~~ 1585  
: 1586

(1) "Veterinarian" means an individual licensed under 1587  
Chapter 4741. of the Revised Code to practice veterinary 1588  
medicine. 1589

(2) "Overdose reversal drug" has the same meaning as in 1590  
section 4729.01 of the Revised Code. 1591

(B) In the course of an emergency medical response, fire 1592  
response, or response to aid law enforcement, a first responder, 1593  
emergency medical technician-basic, emergency medical 1594  
technician-intermediate, or emergency medical technician- 1595  
paramedic may provide any of the following emergency medical 1596  
services to a dog or cat prior to the dog or cat being 1597  
transferred to a veterinarian for further treatment, but only to 1598  
the extent that the first responder, EMT-basic, EMT-I, or 1599  
paramedic is authorized by this chapter or rules adopted 1600  
pursuant to this chapter to perform the corresponding form of 1601  
each of the services when providing emergency medical services 1602  
to a human patient: 1603

(1) Opening and manually maintaining an airway;	1604
(2) Giving mouth to snout or mouth to barrier ventilation;	1605
(3) Administering oxygen;	1606
(4) Managing ventilation by mask;	1607
(5) Controlling hemorrhage with direct pressure;	1608
(6) Immobilizing fractures;	1609
(7) Bandaging;	1610
(8) Administering <del>naloxone hydrochloride</del> <u>an overdose reversal drug</u> , if administering the drug has been authorized by the medical director or cooperating physician advisory board of an emergency medical service organization and the drug is administered either in accordance with a written protocol established and provided by a veterinarian or pursuant to a consultation with a veterinarian.	1611 1612 1613 1614 1615 1616 1617
(C) In addition to the immunity from civil liability granted under division (A) of section 4765.49 of the Revised Code, a first responder, EMT-basic, EMT-I, paramedic, or medical director or member of a cooperating physician advisory board of an emergency medical service organization is not subject to prosecution in a criminal proceeding or professional disciplinary action allegedly arising from an act or omission associated with the provision of emergency medical services to a dog or cat under this section, unless the act or omission constitutes willful or wanton misconduct.	1618 1619 1620 1621 1622 1623 1624 1625 1626 1627
(D) (1) An emergency medical service organization is not liable for or subject to any of the following that allegedly arises from an act or omission associated with the provision of emergency medical services to a dog or cat under this section,	1628 1629 1630 1631

unless the act or omission constitutes willful or wanton 1632  
misconduct: damages in a civil action for injury, death, or loss 1633  
to person or property; prosecution in a criminal proceeding; or 1634  
professional disciplinary action. 1635

(2) The state board of pharmacy shall not take 1636  
disciplinary action against an emergency medical service 1637  
organization's license issued under Chapter 4729. of the Revised 1638  
Code as a terminal distributor of dangerous drugs for reasons 1639  
arising from an act or omission associated with the provision of 1640  
emergency medical services to a dog or cat under this section, 1641  
unless the act or omission constitutes willful or wanton 1642  
misconduct. 1643

(E) (1) Notwithstanding any conflicting provision of 1644  
Chapter 4741. of the Revised Code or rule adopted by the state 1645  
veterinary medical licensing board, a veterinarian may establish 1646  
and provide a written protocol to, or consult with, a first 1647  
responder, EMT-basic, EMT-I, or paramedic for the purpose of 1648  
enabling the provision of emergency medical services to a dog or 1649  
cat under this section. 1650

(2) A veterinarian who acts in good faith in accordance 1651  
with this section is not liable for or subject to any of the 1652  
following for any act or omission associated with a first 1653  
responder's, EMT-basic's, EMT-I's, or paramedic's provision of 1654  
emergency medical services to a dog or cat under this section: 1655  
damages in any civil action; prosecution in any criminal 1656  
proceeding; or professional disciplinary action." 1657

In line 135, after "sections" insert "2925.61, 3707.56, 3707.561, 1658  
3707.562,"; delete "and" and insert ","; after "3719.06" insert ", 1659  
4723.484, 4723.485, 4723.486, 4729.01, 4729.29, 4729.44, 4729.51, 1660  
4729.511, 4729.514, 4729.515, 4729.541, 4730.434, 4730.435, 4730.436, 1661

4731.94, 4731.941, 4731.942, 4731.943, 4765.44, 4765.45, and 4765.52" 1662

After line 136, insert: 1663

**"Section 3.** The General Assembly, applying the principle 1664  
stated in division (B) of section 1.52 of the Revised Code that 1665  
amendments are to be harmonized if reasonably capable of 1666  
simultaneous operation, finds that the following sections, 1667  
presented in this act as composites of the sections as amended 1668  
by the acts indicated, are the resulting versions of the 1669  
sections in effect prior to the effective date of the sections 1670  
as presented in this act: 1671

Section 4729.01 of the Revised Code as amended by H.B. 24, 1672  
H.B. 197, H.B. 203, H.B. 231, H.B. 341, and S.B. 57, all of the 1673  
133rd General Assembly. 1674

Section 4729.51 of the Revised Code as amended by both 1675  
H.B. 231 and H.B. 341 of the 133rd General Assembly. 1676

Section 4729.541 of the Revised Code as amended by H.B. 1677  
231, H.B. 341, and S.B. 276, all of the 133rd General Assembly." 1678

The motion was \_\_\_\_\_ agreed to.

SYNOPSIS 1679

**Overdose reversal drug (terminology change)** 1680

**R.C. 4729.01; conforming changes in other sections** 1681

Defines "overdose reversal drug" as naloxone and any other 1682  
drug that the Pharmacy Board designates through rules as a drug 1683  
that is approved by the federal Food and Drug Administration for 1684

the reversal of a known or suspected opioid-related overdose.	1685
Replaces existing references to "naloxone" in the Revised Code with "overdose reversal drug."	1686
	1687